Clinical Trial WatchDeveloping
An Anti-TL1A Antibody Hit a Phase 3 Remission Endpoint in Ulcerative Colitis
Tulisokibart reportedly met a Phase 3 clinical remission endpoint in ulcerative colitis, making it a watch item for inflammatory bowel disease.
Why now
This is publishable because Merck's June 22 topline release says tulisokibart became the first anti-TL1A monoclonal antibody to demonstrate clinical remission at 12 weeks in a Phase 3 ulcerative colitis study. That creates a platform-level story beyond one IBD drug: anti-TL1A has moved from crowded immunology thesis to late-stage proof point. The boundary is that topline remission language is not approval, not full data, and not a safety profile.
- Overclaim risk
- medium-high
- Primary source
- Trade news
- Published
- Jun 28, 2026